2. Signaling Pathways
  3. Immunology/Inflammation
  4. TREM receptor

TREM receptor

Triggering receptors expressed on myeloid cells

The Triggering Receptor Expressed on Myeloid cells (TREM) family consists of several receptors expressed on the surface of myeloid cells, among which TREM-1 and TREM-2 are the most extensively studied. TREM-1 acts as an amplifier of immune responses, significantly enhancing the responses of macrophages and neutrophils to bacteria and fungi, and promoting the release of inflammatory cytokines such as TNF-α and IL-1β, thus playing a crucial role in acute inflammation and infection responses. Modulating TREM-1 signaling can alleviate the severity of sepsis. TREM-2 helps regulate immune responses by promoting the anti-inflammatory and repair functions of macrophages, maintaining tissue stability, particularly in neural tissues, where the function of TREM-2 is closely associated with slowing the progression of neurodegenerative diseases like Alzheimer’s disease.
The Triggering Receptor Expressed on Myeloid cells interacts with its adaptor protein DAP12 to initiate signaling pathways, including those involving the tyrosine kinase Syk, which in turn activates a variety of downstream cellular responses, including the production of inflammatory cytokines, enhancement of cell survival signals, and reorganization of the cytoskeleton. The Triggering Receptor Expressed on Myeloid cells and their adaptor proteins are not only crucial for understanding immune regulation mechanisms but also provide new targets for the study of various diseases, including inflammatory and neurodegenerative diseases[1].

TREM receptor Isoform Specific Products:

TREM receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P11077
    LR-17
    		Inhibitor
    LR-17 (TLT-1 (94-110)), a 17-aa peptide, is a TREM-1 inhibitor. LR-17 shows anti-inflammatory effects that can reduce the secretion of pro-inflammatory cytokines induced by Lipopolysaccharides (HY-D1056) (LPS). LR-17 can be used for the study of sepsis.
    LR-17
  • HY-P991442
    DNL-919
    		Agonist
    DNL-919 (TAK-920) is a human IgG1 monoclonal antibody (mAb) targeting TREM-2. DNL-919 can be used in Alzheimer's disease research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
    DNL-919
  • HY-10227S
    Bortezomib-d8
    		Inhibitor 98.0%
    Bortezomib-d8 is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
    Bortezomib-d<sub>8</sub>
  • HY-P991174
    Anti-TREM2 Antibody (AL2p-58)
    		Inhibitor
    Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody targeting TREM2. Anti-TREM2 Antibody (AL2p-58) can be used for the research of neuroinflammation. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-TREM2 Antibody (AL2p-58)
  • HY-P991754
    Anti-Mouse TREM2 Antibody (178)
    		Inhibitor 98.92%
    Anti-Mouse TREM2 Antibody (178) reacts with mouse TREM-2 that inhibits TREM-2 both in vivo and in vitro. Recommend Isotype Controls: Rat IgG2a kappa, Isotype Control (HY-P990679).
    Anti-Mouse TREM2 Antibody (178)
  • HY-P991029
    Sutacimig
    		99.08%
    Sutacimig (HMB-001) is a humanized antibody of the (H-γ4_L-κ)_(H-γ4_L-κ) format that targets FⅦa/TREML1. One arm of Sutacimig binds to endogenous FVIIa, thereby prolonging the half-life of FVIIa and increasing its accumulation in the bloodstream, while the other arm binds to TLT-1, which is exclusively expressed on the surface of activated platelets. This localizes endogenous FVIIa to activated platelets, further enhancing the activity of FVIIa. Sutacimig enhances Thrombin generation, fibrin formation, and the formation of stable fibrin-platelet networks at sites of vascular injury. Sutacimig can be used in studies related to Glanzmann thrombasthenia.
    Sutacimig
  • HY-P10938
    LP17 (human)
    		Inhibitor
    LP17 (human) is a TREM1 antagonist peptide with anti-inflammatory and anti-cancer effects.
    LP17 (human)
  • HY-P991905
    AL044
    		Activator
    AL044 is an antibody targeting MS4A family proteins. AL044 can mimic the protective effects of MS4A gene variants, thereby increasing the expression of both sTREM2 and membrane-bound TREM2 in cells. AL044 is applicable for research on Alzheimer's disease.
    AL044
  • HY-182756
    TREM2 modulator-1
    		Modulator
    TREM2 modulator-1 is a TREM2 modulator with an EC50 categorized as A and Emax of ++, and can be found in relevant research contexts. TREM2 modulator-1 modulates Triggering Receptor Expressed on Myeloid Cells 2. TREM2 modulator-1 can be used for the research of neurodegenerative diseases.
    TREM2 modulator-1
  • HY-10227G
    Bortezomib (GMP)
    		Inhibitor
    Bortezomib (GMP) (PS-341 (GMP)) is Bortezomib (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
    Bortezomib (GMP)
  • HY-W010270A
    Aurothiomalate disodium
    		Activator
    Aurothiomalate (disodium) is a TRPA1 inhibitor. Aurothiomalate (disodium) inhibits NF-κB activation and iNOS expression. Aurothiomalate (disodium) promotes M2 transformation of macrophages and increases the expression of TREM-2 and arginase-1. Aurothiomalate (disodium) can be used in the study of liver fibrosis/cirrhosis and arthritis.
    Aurothiomalate disodium
  • HY-P10220
    NOTA-COG1410
    		Ligand
    NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting ligand. NOTA-COG1410 is capable of being labelled with 68Gallium (68Ga) for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography (PET/CT). NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    NOTA-COG1410
  • HY-P10088
    Mouse TREM-1 SCHOOL peptide, control
    		Control
    Mouse TREM-1 SCHOOL peptide, control is a negative control of Mouse TREM-1 SCHOOL peptide.
    Mouse TREM-1 SCHOOL peptide, control
  • HY-N9164
    Hecubine
    		Activator
    Hecubine is a monoterpene indole alkaloid found in Ervatamia ocinalis. Hecubine activates TREM2 expression, reduces LPS (HY-D1056)-stimulated inammatory cytokines (TNF-α、IL-6、IL-1β) overexpression, as well as suppresses the levels of TLR4-, MyD88-, MAPK/PI3K/AKT- and NF-κB-related proteins. Hecubin also exhibits antioxidative effect, reduces ROS production and activates of the Nrf2/HO-1 pathway. Hecubine rescues LPS-induced behavioral deficits in zebrash larvae. Hecubine can be used for the research of neural inflammation-associated central nervous system diseases.
    Hecubine
TREM receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.